Heart failure (HF) is a common and serious
comorbidity of diabetes. Oxidative stress has
been associated with the pathogenesis of
chronic diabetic complications including cardiomyopathy.
The ability of antioxidants to
inhibit injury has raised the possibility of new
therapeutic treatment for diabetic heart diseases.
Riboflavin constitutes an essential
nutrient for humans and animals and it is an
important food additive. Riboflavin, a precursor
of flavin mononucleotide (FMN) and flavin
adenine dinucleotide (FAD), enhances the
oxidative folding and subsequent secretion of
proteins. The objective of this study was to
investigate the cardioprotective effect of
riboflavin in diabetic rats. Diabetes was
induced in 30 rats by a single injection of
streptozotocin (STZ) (70 mg /kg). Riboflavin
(20 mg/kg) was orally administered to animals
immediately after induction of diabetes and
was continued for eight weeks. Rats were
examined for diabetic cardiomyopathy by left
ventricular (LV) remadynamic function.
Myocardial oxidative stress was assessed by measuring the activity of superoxide dismutase (SOD), the level of malondialdehyde (MDA) as well as heme oxygenase-1 (HO-1) protein level. Myocardial connective tissue growth factor (CTGF) level was measured by Western blot in all rats at the end of the study. In the untreated diabetic rats, left ventricular systolic pressure (LVSP) rate of pressure rose (+dp/dt), and rate of pressure decay (−dp/dt) were depressed while left ventricular enddiastolic pressure (LVEDP) was increased, which indicated the reduced left ventricular contractility and slowing of left ventricular relaxation. The level of SOD decreased, CTGF and HO-1 protein expression and MDA content rose. Riboflavin treatment significantly improved left ventricular systolic and diastolic function in diabetic rats, there were persistent increases in significant activation of SOD and the level of HO-1 protein, and a decrease in the level of CTGF. These results suggest that riboflavin treatment ameliorates myocardial function and improves heart oxidant status, whereas raising myocardial HO-1 and decreasing myocardial CTGF levels have beneficial effects on diabetic cardiomyopathy.
Riboflavin, diabetic cardiomyopathy, heme oxygenase-1.
Guoguang Wang, Department of Pathophysiology, Wannan Medical College, Wuhu 241000, China. E-mail: firstname.lastname@example.org.
Share this Article
Related Content In Heart Failure
Sodium–glucose Cotransporter 2 Inhibitors’ Rise to the Backbone of Heart Failure Management: A Clinical Review
Heart International. 15(1):Online ahead of journal publication
Heart failure (HF) is an increasingly prevalent clinical syndrome resulting from a variety of disease processes impeding the heart’s ability to effectively circulate blood. With advances in care and a steadily growing and aging population, HF management is becoming a foremost priority in developed nations like the USA, where HF is expected to affect more […]
Ambulatory Management of Worsening Heart Failure: Current Strategies and Future Directions
Heart International. 2021;15(1):Online ahead of journal publication
Heart failure (HF) is a highly prevalent and morbid disease in the USA, imposing a significant burden on patients, hospitals and the health system. The prevalence of HF continues to increase, with over 650,000 new HF cases diagnosed annually.1 There are over 6.2 million people with HF in the USA,2 with an expected increase to 8 million […]
Explaining Sex Differences in Cardiac Resynchronisation Therapy Outcome
European Journal of Arrhythmia & Electrophysiology. 2020;6(1):17-23 DOI: https://doi.org/10.17925/EJAE.2020.6.1.17
Over the past years, several reports have drawn attention to the need to consider sex-specific differences in cardiac resynchronisation therapy (CRT). Most importantly, there is growing concern on the underrepresentation of women in CRT landmark trials which laid the foundation for present guidelines. Patients with symptomatic heart failure, reduced left ventricular ejection fraction (LVEF) ≤35% […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!